2023 World Conference on Lung Cancer (Posters)-P2.05. A Seven-Lnc RNA Signature for Prognosis Prediction of Patients with Lung Squamous Cell Carcinoma through Tumor Immune Escape

P2.05. A Seven-Lnc RNA Signature for Prognosis Prediction of Patients with Lung Squamous Cell Carcinoma through Tumor Immune Escape - PDF(Abstract)

Back to course

Pdf Summary

This study focuses on lung squamous cell carcinoma (LUSC), a type of lung cancer with a poor prognosis and limited treatment options. The researchers aimed to identify a prognostic model using long non-coding RNAs (LncRNAs) to predict patient outcomes and understand the role of tumor immune escape in LUSC.<br /><br />They analyzed LncRNA expression and clinical data from 471 patients with LUSC from the Cancer Genome Atlas database. The patients were divided into high-risk and low-risk groups based on a risk score calculated using a model constructed from the training group. The high-risk group had significantly worse overall survival compared to the low-risk group.<br /><br />The researchers also assessed the predictive ability of the risk-score using different statistical measures such as the ROC curve and nomogram. The risk-score showed good predictive ability for 1, 3, and 5-year survival in LUSC patients. They also found that the risk group, stage, and age were independent predictors of survival in LUSC patients.<br /><br />Further analysis showed that the seven identified LncRNAs were involved in immune escape mechanisms, indicating their potential role in tumor progression and treatment resistance. Functional enrichment analysis revealed pathways related to chemical carcinogenesis, immune cell differentiation, and signaling pathways in cancer affected by these LncRNAs.<br /><br />Additionally, the researchers used CIBERSORT analysis to compare the immune cell composition between normal and LUSC cells. They found that the immune system in LUSC patients was significantly activated, suggesting an ineffective immune response.<br /><br />In conclusion, this study highlights the clinical significance of a seven-LncRNA signature in predicting survival outcomes in LUSC patients. It also provides insights into the role of immune escape in LUSC, which may have implications for developing targeted therapies.

Asset Subtitle

Zhong Lin

Meta Tag

Speaker Zhong Lin

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

LUSC

prognostic model

long non-coding RNAs

patient outcomes

tumor immune escape

overall survival

risk score

predictive ability

tumor progression

targeted therapies